Skip to main content
SpringerLink
Log in

Acetyl-dl-leucine improves restless legs syndrome: a case report

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Code availability

Not applicable.

References

  1. Schoser B, Schautzer F, Bremova T, Strupp M (2019) Treatment of restless legs syndrome with acetyl-DL-leucine: accidental findings and a small case series. Eur J Neurol 26:348

    Article  Google Scholar 

  2. Walters AS, LeBrocq C, Dhar A et al (2003) Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 4:121–132

    Article  Google Scholar 

  3. Kaya E, Smith DA, Smith C, Boland B, Strupp M, Platt FM (2020) Beneficial effects of acetyl-DL-leucine (ADLL) in a mouse model of Sandhoff disease. J Clin Med 8:9

    Google Scholar 

  4. Hegdekar N, Lipinski MM, Sarkar C (2021) N-acetyl-L-leucine improves functional recovery and attenuates cortical cell death and neuroinflammation after traumatic brain injury in mice. Sci Rep 11:9249

    Article  CAS  Google Scholar 

  5. Vibert N, Vidal PP (2001) In vitro effects of acetyl-DL-leucine (tanganil) on central vestibular neurons and vestibulo-ocular networks of the guinea-pig. Eur J Neurosci 13:735–748

    Article  CAS  Google Scholar 

  6. Gunther L, Beck R, Xiong G et al (2015) N-acetyl-L-leucine accelerates vestibular compensation after unilateral labyrinthectomy by action in the cerebellum and thalamus. PLoS ONE 10:e0120891

    Article  Google Scholar 

  7. Kocar TD, Möller HP, Kassubek J (2020) Differential functional connectivity in thalamic and dopaminergic pathways in restless legs syndrome: a meta-analysis. Ther Adv Neurol Disord 13:1756286420941670

    Article  Google Scholar 

Download references

Funding

The authors did not receive support from any organization for the submitted work.

Author information

Authors and Affiliations

  1. IntraBio Ltd, Begbroke Science Park, Begbroke Hill, Woodstock Road, Oxford, OX5 1PF, UK

    Taylor Fields

  2. Department of Neurology, Friedrich-Baur Institute, Hospital of the Ludwig-Maximilians University, Munich, Germany

    Benedikt Schoser

  3. Deparment of Neurology, University Hospital Marburg, Marburg, Germany

    Wolfgang Oertel

  4. Department of Neurology, Hospital of the Ludwig-Maximilians University, Munich, Germany

    Michael Strupp

Authors
  1. Taylor Fields
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benedikt Schoser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wolfgang Oertel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Strupp
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TF: writing–original draft preparation; writing–reviewing and editing. BS: reviewing and editing. WO: reviewing and editing. MS: conceptualization and methodology; writing–original draft preparation; writing–reviewing and editing.

Corresponding author

Correspondence to Taylor Fields.

Ethics declarations

Conflicts of interest

Taylor Fields is an officer and shareholder of IntraBio. Benedikt Schoser has received out of the scope of this report research grants from the European Union, Federal Ministry of Education and Research Germany; Sanofi-Genzyme, Amicus. Scientific advisory board fees, consulting fees, and speaker fees from Amicus, Alexion, Argenx, Audentes, Dyne, Lupin, Sanofi-Genzyme, UCB. Wolfgang Oertel has received grants from the ParkinsonFonds Deutschland, the Michael J Fox Foundation, and the Deutsche Forschungsgemeinschaft (DFG) outside the submitted work; he has received personal fees for educational and scientific presentations and/or for participating in advisory board meetings from Adamas, Desitin, MODAG, Roche and UCB outside the submitted work. Wolfgang Oertel is Hertie-Senior-Research Professor supported by the Charitable Hertie-Foundation, Frankfurt/Main, Germany. Michael Strupp is a shareholder to IntraBio, and consultant for Abbott, Actelion, AurisMedical, Heel, IntraBio and Sensorion out of the scope of this work; he has received speaker’s honoraria from Abbott, Actelion, Auris Medical, Biogen, Eisai, Grünenthal, GSK, Henning Pharma, Interacoustics, Johnson & Johnson, MSD, Otometrics, Pierre-Fabre, TEVA, UCB and Viatris outside of the work submitted. He is the distributor of M-glasses and positional vertigo App.

Ethical approval

Not applicable since description of a single case of individual off-label treatment. Written consent by the patient for compassionate-use of N-acetyl-DL-leucine.

Consent for publication

All authors had full access to the data in the case report and had final responsibility for the decision to submit for publication.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fields, T., Schoser, B., Oertel, W. et al. Acetyl-dl-leucine improves restless legs syndrome: a case report. J Neurol 268, 2595–2596 (2021). https://doi.org/10.1007/s00415-021-10625-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-021-10625-3

Search

Navigation